清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

骨髓纤维化 达那唑 医学 胃肠病学 双盲 内科学 安慰剂 病理 子宫内膜异位症 替代医学 骨髓
作者
Srđan Verstovšek,Aaron Thomas Gerds,Alessandro Maria Vannucchi,Haifa Kathrin Al‐Ali,David Lavie,Andrew Tucker Kuykendall,Sebastian Grosicki,Alessandra Iurlo,Yeow Tee Goh,Mihaela Cornelia Lazaroiu,Miklós Egyed,María Laura Fox,Donal P. McLornan,Andrew Charles Perkins,Sung‐Soo Yoon,Vikas K Gupta,Jean‐Jacques Kiladjian,Nikki Granacher,Sung‐Eun Lee,Luminita Ocroteala
出处
期刊:The Lancet [Elsevier BV]
卷期号:401 (10373): 269-280 被引量:233
标识
DOI:10.1016/s0140-6736(22)02036-0
摘要

Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients with anaemia and intermediate-risk or high-risk myelofibrosis.MOMENTUM is an international, double-blind, randomised, controlled, phase 3 study that enrolled patients at 107 sites across 21 countries worldwide. Eligible patients were 18 years or older with a confirmed diagnosis of primary myelofibrosis or post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. Patients were randomly assigned (2:1) to receive momelotinib (200 mg orally once per day) plus danazol placebo (ie, the momelotinib group) or danazol (300 mg orally twice per day) plus momelotinib placebo (ie, the danazol group), stratified by total symptom score (TSS; <22 vs ≥22), spleen size (<12 cm vs ≥12 cm), red blood cell or whole blood units transfused in the 8 weeks before randomisation (0 units vs 1-4 units vs ≥5 units), and study site. The primary endpoint was the Myelofibrosis Symptom Assessment Form (MFSAF) TSS response rate at week 24 (defined as ≥50% reduction in mean MFSAF TSS over the 28 days immediately before the end of week 24 compared with baseline). MOMENTUM is registered with ClinicalTrials.gov, number NCT04173494, and is active but not recruiting.195 patients were randomly assigned to either the momelotinib group (130 [67%]) or danazol group (65 [33%]) and received study treatment in the 24-week randomised treatment period between April 24, 2020, and Dec 3, 2021. A significantly greater proportion of patients in the momelotinib group reported a 50% or more reduction in TSS than in the danazol group (32 [25%] of 130 vs six [9%] of 65; proportion difference 16% [95% CI 6-26], p=0·0095). The most frequent grade 3 or higher treatment-emergent adverse events with momelotinib and danazol were haematological abnormalities by laboratory values: anaemia (79 [61%] of 130 vs 49 [75%] of 65) and thrombocytopenia (36 [28%] vs 17 [26%]). The most frequent non-haematological grade 3 or higher treatment-emergent adverse events with momelotinib and danazol were acute kidney injury (four [3%] of 130 vs six [9%] of 65) and pneumonia (three [2%] vs six [9%]).Treatment with momelotinib, compared with danazol, resulted in clinically significant improvements in myelofibrosis-associated symptoms, anaemia measures, and spleen response, with favourable safety. These findings support the future use of momelotinib as an effective treatment in patients with myelofibrosis, especially in those with anaemia.Sierra Oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wei发布了新的文献求助10
1秒前
Yuna发布了新的文献求助10
2秒前
清爽水之完成签到,获得积分10
8秒前
贪玩鸣凤完成签到,获得积分10
29秒前
哈哈哈哈完成签到 ,获得积分10
31秒前
孝顺的丹烟完成签到,获得积分10
39秒前
39秒前
王誉霖发布了新的文献求助10
41秒前
46秒前
楚楚完成签到 ,获得积分10
48秒前
50秒前
王誉霖完成签到,获得积分10
51秒前
大方定帮完成签到,获得积分10
1分钟前
合适乐巧完成签到 ,获得积分10
1分钟前
缓慢凛完成签到,获得积分10
1分钟前
ghost完成签到 ,获得积分10
1分钟前
稳重傲柔完成签到,获得积分10
1分钟前
万能图书馆的应助被边疆采纳,获得10
1分钟前
温柔的海秋完成签到,获得积分10
1分钟前
1分钟前
任性的千筹完成签到,获得积分10
1分钟前
边疆发布了新的文献求助10
1分钟前
单薄飞双完成签到,获得积分10
1分钟前
Jzhaoc580完成签到 ,获得积分10
1分钟前
边疆完成签到,获得积分10
2分钟前
2分钟前
麦子发布了新的文献求助10
2分钟前
李木禾完成签到 ,获得积分10
2分钟前
Hello的应助被麦子采纳,获得10
2分钟前
俭朴迎荷完成签到,获得积分10
2分钟前
2分钟前
今后的应助被catalyst326采纳,获得10
2分钟前
冥土追魂发布了新的文献求助10
2分钟前
震动的醉蓝完成签到,获得积分10
2分钟前
慕青的应助被冥土追魂采纳,获得10
2分钟前
Jasper的应助被wei采纳,获得10
2分钟前
星辰大海的应助被好牛采纳,获得10
2分钟前
jingluo完成签到 ,获得积分10
2分钟前
3分钟前
平淡水之完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166463
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750516
捐赠科研通 7757246
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553507
邀请新用户注册赠送积分活动 2473845